医学
突变体
癌症
肿瘤科
内科学
数据库
免疫检查点
癌症研究
基因
免疫疗法
遗传学
生物
计算机科学
作者
Xuanzong Li,Ruozheng Wang,Linlin Wang
出处
期刊:Lung Cancer
[Elsevier BV]
日期:2020-09-30
卷期号:150: 256-258
被引量:6
标识
DOI:10.1016/j.lungcan.2020.09.021
摘要
In the article by Yang et al. [ [1] Yang H. Zhou Z. Lin L. Yang M. Li C. Li Z. Yu X. Lizaso A. Han-Zhang H. Li B. Xiang J. Mao X. Xu Q. Zhang Y. Yang N. Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers. Lung Cancer (Amsterdam, Netherlands). 2020; 148: 113-121 Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar ], it was identified that lung cancer patients with MET exon 14 (METex14) alterations achieve longer progression-free survival on crizotinib than on chemotherapy. Unfortunately, there were no significant differences in overall survival between these two subgroups. In addition, the prevalence of METex14 alterations was only 1.1 % in Chinese lung cancer patients, and the therapeutic strategies for cancers with MET non-ex14 mutations, such as MET kinase domain or semaphorin domain mutations, are still largely unknown. Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersLung CancerVol. 148PreviewLung cancer is a leading cause of cancer deaths worldwide [1–3]. In the past decade, the treatment landscape of lung cancer has been revolutionized by the development of targeted therapies. With advancements in the understanding of oncogenic driver mutations such as EGFR [4–6], ALK [7–9], and ROS1 [10], targeted therapies have generated impressive clinical outcomes and prolonged the median overall survival to 3.5 years in advanced patients harboring these driver mutations [11]. Furthermore, the landscape of targeted therapy continues to evolve with the identification of novel actionable mutations. Full-Text PDF A reply to “MET-mutant cancer and immune checkpoint inhibitors: A large database analysis”Lung CancerVol. 150PreviewWe would like to thank Xuanzong Li and colleagues for their interest in our recent publication entitled “Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers”. The major aims of our study were to investigate the prevalence of MET exon 14 alterations and the therapeutic efficacy of crizotinib in MET exon 14-altered Chinese lung cancers [1]. As was expected, the progression-free survival (PFS) of patients treated with crizotinib was longer than patients treated with chemotherapy; however, their overall survival (OS) was not statistically different. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI